Federal District Court Rochester, N.Y. entrance and building-mounted sign
A federal district judge in Rochester, N.Y., has dismissed two community health centers’ antitrust suit against insulin manufacturers over the companies’ 340B pricing policies.

Judge Dismisses 340B Contract Pharmacy-Related Antitrust Claims Against Insulin Manufacturers

A federal district judge has dismissed two community health centers’ federal and state antitrust claims against four insulin and diabetes drug manufacturers over the companies’ denials of 340B pricing when covered entities use contract pharmacies.

Chief Judge Elizabeth Wolford of U.S. District Court for the District of Western New York on Sept. 2 agreed with AstraZeneca, Lilly, Novo Nordisk, and Sanofi that New York state health center Mosaic Health and Virginia-based Central Virginia Health Services’ (CVHS) “failed to plausibly allege” that the four companies illegally colluded to deny 340B pricing on insulin and other diabetes medicines, in violation of federal and state laws.

A federal district judge has dismissed two community health centers’ federal and state antitrust claims against four insulin and diabetes drug manufacturers over the companies’ denials of 340B pricing when covered entities use contract pharmacies.

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now.
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.
« Read Previous Read Next »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

×

*Sign up for news summaries and alerts from 340B Report

Site Footer